CLEC9A and cancer: Cancer immune evasion can occur through tumor-derived prostaglandin E2 (PGE2) that impairs cDC1 function as well as tumor-secreted gelsolin that reduces CLEC9A binding to dead cell fragments, thus affecting cDC1-mediated cross-presentation [40, 55].